Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD Inc. (NSPR) is a medical device company pioneering MicroNet stent technology for stroke prevention through advanced carotid artery treatments. This page serves as the definitive source for verified corporate announcements, clinical developments, and strategic updates.
Investors and medical professionals will discover timely updates including FDA regulatory progress, international clinical trial results, product launch details, and partnership announcements. All content undergoes rigorous verification to ensure accuracy and relevance to stakeholder decision-making.
The resource features critical developments in vascular intervention technology, including innovations in embolic protection systems and expansion into new global markets. Users can track the company's progress through major clinical study publications and regulatory milestone achievements.
Bookmark this page for structured access to InspireMD's latest verified news. Check regularly for updates on carotid stenting advancements, financial disclosures, and evidence-based medical device innovations shaping stroke prevention care.
InspireMD (Nasdaq: NSPR) announced results from the SIBERIA randomized clinical trial demonstrating the effectiveness of its CGuard MicroNet-covered stent in reducing silent brain infarcts compared to the conventional Acculink stent. The study showed a 57% reduction in lesions and a 4.5-fold reduction in total infarct volume. The findings, published in the JACC, provide level 1 evidence favoring CGuard in preventing cerebral embolization. InspireMD’s CEO expressed optimism about the technology potentially changing standard care for carotid artery disease.
InspireMD (Nasdaq: NSPR) will announce its third quarter 2021 financial results on November 9, 2021, before market opening. The company, known for its CGuard™ Embolic Prevention Stent System, will host a conference call at 8:30 a.m. ET on the same day to discuss results and corporate updates. Interested parties can participate via toll-free and international numbers or access a live webcast on the company’s website.
InspireMD (NSPR) announced that its CGuard EPS stent system has received a positive reimbursement opinion from the French National Authority for Health (HAS), effective October 25, 2021. This milestone marks a crucial step towards the commercial launch of CGuard EPS, previously approved by CNEDIMTS for use in treating carotid artery disease. The stent aims to enhance treatment options, moving away from surgical methods. InspireMD's unique MicroNet technology is designed to improve patient outcomes.
InspireMD, developer of the CGuard™ Embolic Prevention System, reported a revenue increase of 231.6% in Q2 2021, totaling $1,038,000 compared to $313,000 in Q2 2020, driven by a recovery in procedural volumes. The gross profit rose to $262,000, with a gross margin of 25.2%. However, operating expenses increased by 59.2% to $3,702,000. The net loss for the quarter was $3,507,000 or $0.46 per share. The company initiated the “C-Guardians” IDE clinical trial, transferring its stock listing to Nasdaq to enhance investor access.
InspireMD (Nasdaq: NSPR) announced it will release its fiscal Q1 2021 financial results on August 10, 2021, before the market opens. A conference call will follow at 8:30 a.m. ET to discuss these results and corporate developments. Participants must pre-register to join, with options for telephonic or webcast access available. The company aims to establish its CGuard™ Embolic Prevention Stent System for treating carotid artery disease and ensure stroke prevention.
InspireMD (Nasdaq: NSPR) has initiated patient enrollment in the U.S. registration C-Guardian trial for its CGuard™ Embolic Prevention Stent System aimed at treating Carotid Artery Disease. The trial anticipates enrolling 315 patients, with the first successful cases completed at Ballad Health System under Dr. Chris Metzger's supervision. InspireMD aims to establish CGuard EPS as a leading stent device in the U.S. market, building on positive prior global outcomes and leveraging its MicroNet® technology for superior patient results.
InspireMD announced that CEO Marvin Slosman will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. The presentation is scheduled for June 9 at 11:30 AM ET on Track 3. Investors can register to watch the presentation here. The company aims to set its MicroNet® technology as the standard for carotid stenting, enhancing stroke-free outcomes. InspireMD's common stock trades on Nasdaq under the symbol NSPR.
InspireMD, Inc. has announced the approval for its warrants, previously traded on NYSE American, to be listed on the Nasdaq Capital Market. Trading under the new symbols NSPRW and NSPRZ is set to commence on June 8, 2021. The company focuses on developing the CGuard™ Embolic Prevention System to prevent strokes from carotid artery disease. InspireMD aims to set a new standard in carotid stenting with its proprietary MicroNet® technology.
InspireMD (Nasdaq-CM: NSPR) announces the commencement of its shares trading on The Nasdaq Capital Market as of May 21, 2021. The Company aims to enhance awareness, broaden its shareholder base, and improve trading liquidity to establish a standard of care in treating Carotid Artery Disease and stroke prevention. CEO Marvin Slosman emphasized the importance of this milestone in the Company's evolution. InspireMD utilizes its proprietary MicroNet technology to provide better outcomes in carotid stenting.
InspireMD, a developer of the CGuard™ Embolic Prevention System for stroke prevention in Carotid Artery Disease, will present at the Investor Summit Conference on May 17, 2021. Chief Executive Officer Marvin Slosman is scheduled to speak at 11:00am ET.
Investors are invited to request one-on-one meetings with Mr. Slosman post-conference. Registration for the event is available here.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
